Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...
US-based Amgen and Tokyo-based Astellas have announced an alliance to provide new medicines to help address serious unmet medical needs of Japanese patients. The two companies will first focus on ...
Q4 2024 Management View Amgen highlighted its robust performance in 2024, achieving 14 products annualizing over $1 billion in sales. CEO Robert Bradway emphasized the company's resilience in ...
Amgen has reported that its once-monthly dosing regimen and manufacturing capabilities will be key to entering the obesity market. Presenting at the JP Morgan Healthcare Conference 2025 on 13 ...
Amgen’s osteoporosis bone-forming drug Evenity (romosozumab) has been approved in Japan, ahead of a crunch review by advisers to the US regulator later this month. Evenity could have been on the ...
Amgen's stock price remains nearly unchanged over 1.5 years, but its valuation may now be more reasonable or even a bargain. Despite high debt from the Horizon Therapeutics acquisition, Amgen ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback